Introduction
Migraine is currently classified by the WHO as being one of the top 20 most debilitating diseases. It is a painful disorder characterized by pulsating head pain lasting from 4 to 72 h accompanied by nausea, vomiting, photophobia, phonophobia or a combination thereof. Attacks are sometimes preceded by visual sensory disturbances known as an aura, lasting 20-30 min before the onset of a migraine attack. The International Headache Society (IHS) subdivides migraine into two major groups, namely, migraine with aura (MA) and migraine without aura (MO) [1] . Migraine affects B12% of the population, with two-thirds of cases being women [2] . Because of the genetic heterogeneity of migraine further complicated by environmental factors, the pathophysiological mechanisms are not yet fully understood. However, a number of hypotheses pertaining to the pathways involved exist and these are being evaluated continually.
Current ideas are based on the theory that activation of the trigeminal nerve system by a neural, vascular or neurovascular trigger leads to a migraine. The trigeminal nerves carry pain signals from the meninges and blood vessels infusing the meninges to the trigeminal nucleus in the brain stem, which in turn sends signals to the sensor cortex through the thalamus. The sensor cortex processes pain signals and other senses, thus leading to the sensation of pain experienced during migraine attacks. The exact process/processes that activates the trigeminal nerves is still being debated [3] . The neuronal hypothesis is based on Leao's ideas originating as early as the 1940s. Leao proposed that cortical spreading depression (CSD) activates the trigeminal nerves and is thereby the phenomenon responsible for migraine attacks. CSD is a wave of neuronal and glial depolarization/neuronal hyperexcitability, followed by a long-lasting suppression of neural activity [4] . This electrophysiological event has been linked to aura in the human visual cortex and is considered to be partly responsible for the sensory and motor disturbances experienced during MA attacks. Even though only 20% of migraine attacks include an aura, a role for CSD has been suggested by the neurovascular hypothesis in the pathogenesis of MO as well.
The neurovascular theory is based on the concept that both vascular and neural stimuli leading to CSD are responsible for migraine attacks. The hypothesis is that meningeal inflammation occurs as a consequence of CSD and local mediators such as calcitonin, gene-related peptide and substance P activate meningeal sensory neurons. It is hypothesized that these neuropeptides rather than vasodilatation are directly responsible for activation of the pain pathway [5] . This theory contradicts the vascular theory upheld by Wolff et al. [6] , which states that the pain sensation is caused directly by the vasodilatation of intracranial and extracranial vessels [7] .
According to the neurovascular hypothesis, neuroinflammation, resulting from the release of inflammatory mediators such as cytokines and mast cells following CSD, may further promote and sustain the activation and sensitization of meningeal nociceptors, inducing the persistent throbbing headache characterized in migraine. Mast cells release proteases and inflammatory mediators, including tumour necrosis factor-a and interleukin-6, upon exposure to sensory neuropeptides [5] . Mast cells are also involved in the synthesis of nitric oxide (NO), which mediates neurotransmission in the central nervous system (CNS). NO contributes towards vasodilatation, increased local blood flow and decreased vascular resistance in cerebral circulation, important for pain perception transmitted through the trigeminal neurons [8] . Because of its role in NO regulation and interleukin release, apolipoprotein E (APOE) has been suggested to play a role in the migraine pathogenesis pathway.
APOE is the protein component of a lipid-protein complex that functions as part of lipid and cholesterol metabolism in the CNS [9, 10] . APOE is involved in the repair of neural and glial membranes and also acts as an antioxidant. It has been shown that APOE increases the production of NO in human monocyte-derived macrophages [11] . As NO is released as part of the response to tissue inflammation and injury, APOE-mediated regulation of NO may be an important link in the tissue inflammation process [12] . As mentioned earlier, it has been hypothesized that an inflammatory response may promote and sustain the activation of meningeal nociceptors during a migraine attack. Investigation of APOE and the role that its variants may play in migraine susceptibility is therefore of interest. Genotyping some of the variants within the APOE gene could delineate whether individuals with a particular APOE isoform have increased susceptibility towards developing migraine.
APOE has three major alleles, APOE E2, APOE E3 and APOE E4, which are transcribed into their respective protein isoforms (APOE e2, APOE e3 and APOE e4) differing by a single amino acid base substitution at 112 and 158 bp, encoding either cysteine or arginine [13] . Studies have examined the potential role of APOE in susceptibility to migraine, but have produced conflicting results. Rainero et al. [14] found that allele frequencies did not differ significantly between migraine patients and controls, but that mixed headache patients showed a significant (P < 0.001) increase of the E2/E4 genotype compared with controls. Conversely, Gupta and colleagues found a higher prevalence of APOE E2 compared with controls (P < 0.001), and suggested that the APOE E2 variant increases the risk of migraine by 2.31%, whereas APOE E4 was found to be protective against migraine (P = 0.01). The aim of this study was to evaluate the potential role of the three APOE alleles in an Australian case-control population by genotyping samples and then using statistical methods to detect whether there are any significant differences between the APOE alleles in cases compared with control samples.
Materials and methods

Sample selection
Approval for the study protocol was obtained from the Griffith University's Ethics Committee for Experimentation on Humans. Patients with migraine (cases) and controls were recruited through the Genomics Research Centre outpatient clinic through various methods including media coverage and advertisements as well as referral by neurologists as described previously [15] . They were all of Caucasian origin, and diagnosed with MA or MO on the basis of the criteria specified by the IHS. An unaffected control group with no family history of migraine was matched for age (±5 years), sex and ethnicity. Blood samples obtained from patients were collected through the Genomics Research Centre patient clinic. A total of 141 cases and 121 controls were genotyped for the APOE isoform variants.
Apolipoprotein E markers
As outlined above, there are three different protein isoforms of APOE that result from two different nucleotide substitutions causing an amino acid change at the protein level. APOE E3, which is the most common form, has a cysteine residue at position 112 and an arginine residue at position 158. APOE E2 differs from APOE E3 because of a nucleotide substitution resulting in Arg158 changing to a cysteine residue. Therefore, APOE E2 contains two cysteine residues: one at position 112 and another at position 158. APOE E4 contains a variant that results in an arginine being present at amino acid position 112. As a result of this variation, APOE E4 contains two arginine residues that introduce a novel cut site into the mRNA transcript for HhaI. Different fragment sizes are produced during enzyme digestion because of this variation.
Molecular analysis
DNA was extracted from blood samples using standard salting-out procedures [16] . PCR was optimized for 0.2 mM oligonucleotide forward (5 0 -ACAGAATTCGCCC CGGCCTGGTACAC-3 0 ) and reverse (5 0 -TAAGCITGG CACGGCTGTCCAAGGA-3 0 ) primers, as well as for 1.5 mM MgCl 2 . Each reaction mix contained reaction buffer, 0.2 mM dNTPs, 1.5 U Mango Taq polymerase and 40 ng of genomic DNA, and was made up to 50 ml with dH 2 O [17] . Cycling conditions were as follows: one cycle at 951C for 5 min, followed by 30 cycles of 951C for 1 min (denaturation), 601C for 1 min (annealing), 721C for 1.5 min (extension) and a final extension at 721C for 5 min.
Restriction fragment length polymorphism was then performed using HhaI, which cuts the recognition sequence GCGC. HhaI cleaves 112arg (E4) and 158arg (E3, E4), but does not cleave the respective cysteine residues associated with E2 and E3. This produces a unique combination of HhaI fragment sizes for each APOE variant. APOE E4 is cleaved into four fragments, 19, 72, 48 and 35 bp long, whereas APOE E3 does not contain the histidine cut site at position 158 and therefore only three fragments of 91, 48 and 35 bp are produced. APOE E2 has cysteine residues at both position 112 and 158, resulting in only two fragment sizes of 91 and 83 bp being produced upon digestion. Restriction fragment length polymorphism reaction mixture, containing 15 ml of PCR product, 0.2 ml of BSA and 1 Â buffer, was mixed with 0.5 ml of HhaI (optimized by titration of 0.3-0.9 mM) and made up to 20 ml with dH 2 O. Each reaction mixture was allowed to digest overnight at 371C and then deactivated for 20 min at 651C. The digested reaction products were then loaded into the 30% w/v polyacrylamide gel alongside a 25 bp ladder and subjected to electrophoresis for 3 h at 90 V. The gel was stained with ethidium bromide for 15 min and visualized under ultraviolet light.
Statistical analysis
Hardy-Weinberg Equilibrium (HWE) was used to test for deviation between observed and expected APOE allele frequencies in both the case and the control population [18] . A w 2 was used to test for an association between APOE alleles E2, E3 and E4 in case versus control samples. Multiallelic marker analysis of each genotype combination was carried out using CLUMP [19] . Results were further analysed according to migraine subtype as classified by the IHS. w 2 analysis and CLUMP were used to test for significant differences in allele and genotype frequencies [18] between MA and MO versus control results.
Results
The distribution of APOE alleles E2, E3 and E4 as well as the distribution of genotype combinations in case and control samples are summarized in Tables 1 and 2, respectively. Both the migraine population (P = 0.791) and the control population (P = 0.087) were found to be in HWE. w 2 analysis comparing APOE alleles E2, E3 and E4 between case and control populations indicated that there was no significant association between any of the APOE variants and migraine. A P value of 0.996 was obtained for this calculation, which is well above the significance threshold level of 0.05.
When multiallelic marker analysis was carried out for the different genotype combinations, it was found that there was no association between any of the APOE genotype combinations and migraine. One thousand Monte Carlo steps with five degrees of freedom and correction for small allele frequencies yielded an output P value of 0.230, which is also well above the threshold level for significance. When results were further broken down and analysed according to migraine subtype, there was also no significant association. [20] findings, we carried out an additional analysis to evaluate any potential association between APOE E2 or APOE E4 and migraine. A further CLUMP analysis of APOE E4 case and control frequencies compared with E3 and E2 case and control frequencies was carried out to test for any association between the APOE E4 allele and migraine. This yielded a P value of 0.834, indicating that there was no association between APOE E4 and migraine in our case-control cohort. Similarly, the APOE E2 case and control frequencies were compared with E3 and E4, which yielded a P value of 0.1428, indicating that there was no association between APOE E2 and migraine in our study.
Discussion
APOE genotype frequencies are consistent throughout the migraine and control population. Our study did not find a significant (P > 0.05 for all subgroups) association between APOE and migraine, contradicting the results reported by Gupta et al. [20] .
Rainero et al. [14] examined the role of the APOE gene in 241 headache patients, 135 MO, 18 MA and 88 mixed headache (MO and tension-type headache), as compared with 587 geographically matched healthy individuals.
This study was carried out in an Italian headache centre and the diagnosis on migraine was made according to IHS criteria. This study found that the allele frequencies did not significantly differ between cases and controls (P = 0.24), whereas mixed headache patients showed a significant (P < 0.001) increase in the E2/E4 genotype compared with the controls [14] . Rainero et al. [14] suggested a possible association between the E2/E4 genotype and the risk it poses for the development of tension-type headache.
More recently, a case-control population study carried out in 2008 [20] found a higher prevalence of APOE E2 compared with controls (P < 0.001), and suggested that the APOE E2 allele increases the risk of migraine by 2.31%, whereas APOE E4 was found to be protective against migraine (P = 0.01). In our study, there was no significant difference between case and control allele frequencies (P = 0.996) or between case and control genotype frequencies (P = 0.230). The APOE E2 allele was found in 8.2% of our case samples and 8.3% of our control samples whereas the APOE E4 allele was found in 13.5% of case samples and 13.2% of control samples. The APOE E3 allele is considered to be the wild-type allele and is found in B77% of individuals from healthy populations, whereas APOE E2 and APOE E4 are considered to be dysfunctional and occur at frequencies of 8 and 15%, respectively [21] . Our data showed a similar allele frequency distribution for both the case and the control population, with patient samples showing an allele frequency distribution of 8.2, 78.4 and 13.5% for the E2, E3 and E4 alleles, respectively. Control samples reflected an almost identical distribution with allele E2, E3 and E4 frequencies of 8.3, 78.5 and 13.2%, respectively. These data reflect an allele frequency distribution that is similar to other control populations.
Limitations of these studies include the deviation in sample size and the variation in ethnic groups (Italian and Indian) used for case and control samples as well as small sample sizes. The positive results could have been a result of population stratification rather than a true association. This is further reflected by the deviation from HWE in Gupta's study. Conversely, our results are in HWE and that there is no deviation from the general population. This is the third study to directly examine the association between APOE variants and migraine and, given our findings, we are able to conclude that although APOE plays a role in the homeostasis of the CNS, from this study, the test APOE genetic marker did not show an association with migraine and susceptibility to migraine.
Conclusion
This study examined the possible association in an Australian population between migraine with and without aura, and the various APOE alleles. There was no significant association between controls and migraine, or migraine subtypes. These findings contradict previous studies and we conclude that according to our findings, the APOE E2 and APOE E3 alleles do not play a significant role in susceptibility to migraine in the tested Australian Caucasian population.
